SkinBioTherapeutics study results fail to excite investors

Life sciences research outfit SkinBioTherapeutics (LON:SBTX) has announced that its SkinBiotix treatment has shown efficacy in its first human study. The treatment was found to be safe and well tolerated in all 129 trial participants over 29 days. However, in most groups the difference in skin condition between the treatment and vehicle outcomes were minor at the end of the test period.

Dr Cath O’Neill, CEO of the AIM-listed company, commented: “We are really pleased by these data. To show efficacy at this stage of development is very exciting since there is a lot of scope for us to further optimise the formulation, potentially altering the dose of the SkinBiotix® to make it more suitable for different age groups.

“It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema“.

Shares in SkinBioTherapeutics fell by 4.50% to 19.10p (as of 13:50 BST).